Haemonetics (NYSE:HAE – Get Rating) had its target price hoisted by Mizuho from $100.00 to $110.00 in a report issued on Tuesday morning, The Fly reports. Mizuho currently has a buy rating on the medical instruments supplier’s stock.
HAE has been the topic of a number of other research reports. Citigroup lifted their price objective on Haemonetics from $88.00 to $92.00 and gave the company a neutral rating in a report on Monday, December 12th. StockNews.com began coverage on Haemonetics in a report on Wednesday, October 12th. They issued a buy rating on the stock. Barrington Research lifted their price target on shares of Haemonetics from $88.00 to $94.00 and gave the company an outperform rating in a research report on Tuesday, November 8th. TheStreet upgraded shares of Haemonetics from a c+ rating to a b rating in a research report on Monday, November 7th. Finally, Raymond James lifted their price target on shares of Haemonetics from $88.00 to $100.00 and gave the company an outperform rating in a research report on Tuesday, November 8th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $97.50.
Haemonetics Stock Performance
NYSE HAE opened at $90.60 on Tuesday. The company has a quick ratio of 1.76, a current ratio of 2.73 and a debt-to-equity ratio of 1.04. Haemonetics has a 52-week low of $43.50 and a 52-week high of $91.36. The business’s 50-day moving average price is $81.62 and its 200 day moving average price is $77.20. The firm has a market cap of $4.59 billion, a P/E ratio of 54.58 and a beta of 0.39.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Cardinal Capital Management raised its position in shares of Haemonetics by 2.3% during the 4th quarter. Cardinal Capital Management now owns 10,780 shares of the medical instruments supplier’s stock worth $848,000 after purchasing an additional 238 shares during the last quarter. Romano Brothers AND Company acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $31,000. Riverwater Partners LLC acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $717,000. North Star Investment Management Corp. acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $739,000. Finally, Bank of New York Mellon Corp raised its position in shares of Haemonetics by 3.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 614,235 shares of the medical instruments supplier’s stock worth $45,472,000 after purchasing an additional 17,929 shares during the last quarter.
Haemonetics Company Profile
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.
- Get a free copy of the StockNews.com research report on Haemonetics (HAE)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.